This author has, for several years, questioned the pharmaceutical sector pricing model, given the enormous power wielded by pharmacy benefit management companies Should a new piece of legislation be passed as proposed, the sector may be revealed as being less than pristine.
http://www.businessinsider.com/ron-wyden-introduces-pharmacy-benefit-managers-transparency-bill-2017-3
It is the assertion of this author that such a bill is both long overdue and badly needed. There may be considerable regulatory scrutiny of the largest publicly traded PBMs once lawmakers determine the extent of their murky pricing practises.
http://www.investopedia.com/news/pharmacy-benefit-managers-and-insulin-makers-face-price-scheme-lawsuit-cvs-esrx/?partner=YahooSA&yptr=yahoo
Leave a Reply
You must be logged in to post a comment.